Please assess the completion status of the following clinical trial:

Trial Title: Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically/cytologically confirmed adenocarcinoma of the breast, followed by adequate surgical resection and/or radiotherapy, and/or adjuvant chemotherapy, if indicated.~* Stage T1-3 N0-2 Mo, Any TNM stage BC for whom adjuvant hormonal therapy is being considered.~Exclusion Criteria:~* Those patients not deemed to have had potentially curative primary surgical treatment or one of the following criteria:~* Inflammatory breast cancer~* Histologically positive supraclavicular nodes~* Ulceration/infiltration of local skin metastasis~* Neoadjuvant chemotherapy~* Ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) without invasion~* ER and PR negative primary tumor or ER/PR unknown status.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- exemestane (Type: EXPERIMENTAL): None
- tamoxifen + exemestane (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).